Safety of Biologics for Psoriatic Patients with Latent Tuberculosis

作者：Liyan Yuan, Yang Li, Junjie Lin, Xiuqiu Lin, Bin Yang, Mao‐Qiang Man, Xiaohua Wang · 发表于：Clinical Cosmetic and Investigational Dermatology · 年份：2023 · DOI：10.2147/ccid.s426253 · 被引用次数：7 · 研究领域：Tuberculosis Research and Epidemiology、Diagnosis and treatment of tuberculosis、Infectious Diseases and Tuberculosis

Although biologics are effective for psoriasis, immunosuppressive therapy can increase the risk of tuberculosis (TB) reactivation.To determine whether biological therapy for psoriasis increases the risk for TB reactivation, we performed a patients' chart review to determine the incidence and the relative risk of TB reactivation in psoriatic patients with latent TB infection (LTBI), who received biological therapy, with vs without prior anti-TB therapy.In addition to routine test for HIV, a total of 1208 patients, including 881 males and 327 females aged 39.0 11.4 years, with moderate-to-severe psoriasis were screened for TB infection prior to biological therapy at our department from January 2020 to June 2021.All patients were negative for HIV and syphilis.LTBI was defined as a positive for Interferon-gamma release assay (IGRA) without any indications of active TB infection according to chest X-rays or CTs, and clinical symptoms.TB reactivation means development of active TB or re-infection of TB in patients who have recovered from previous TB infection.All patients included in this analysis were positive for Interferon-gamma release assay, without any indications of active TB infection at baseline, indicating that they had recovered from previous TB infection.TB reactivation was diagnosed by specialists at the Chest Hospital, based on the findings of chest CTs or X-rays, and clinical symptoms.Of 180 patients who were LTBI (IGRA positive), 69 patients were given prophylaxis t...